PetMed Express, Inc. (NASDAQ:PETS) Shares Bought by Metavasi Capital LP

Metavasi Capital LP boosted its stake in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 48.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 340,302 shares of the company's stock after acquiring an additional 111,194 shares during the period. PetMed Express accounts for approximately 0.6% of Metavasi Capital LP's holdings, making the stock its 25th biggest holding. Metavasi Capital LP owned 1.65% of PetMed Express worth $1,640,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of PetMed Express in the 4th quarter worth approximately $31,000. Quarry LP bought a new position in PetMed Express in the fourth quarter worth $47,000. Virtu Financial LLC purchased a new position in PetMed Express during the fourth quarter valued at $58,000. Boothbay Fund Management LLC bought a new stake in shares of PetMed Express during the 4th quarter valued at $59,000. Finally, Diametric Capital LP purchased a new stake in shares of PetMed Express in the 4th quarter worth about $86,000. 73.33% of the stock is currently owned by institutional investors.

PetMed Express Stock Performance

Shares of NASDAQ PETS traded up $0.14 during trading on Friday, hitting $3.62. The company had a trading volume of 113,397 shares, compared to its average volume of 289,474. The stock has a 50 day simple moving average of $3.72 and a 200 day simple moving average of $4.45. The firm has a market capitalization of $74.77 million, a P/E ratio of 362.36 and a beta of 0.99. PetMed Express, Inc. has a 12 month low of $2.90 and a 12 month high of $6.85.

PetMed Express (NASDAQ:PETS - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.02). PetMed Express had a return on equity of 0.37% and a net margin of 0.14%. As a group, analysts predict that PetMed Express, Inc. will post 0.19 EPS for the current year.

Analyst Upgrades and Downgrades

PETS has been the subject of a number of recent research reports. StockNews.com downgraded PetMed Express from a "buy" rating to a "hold" rating in a report on Wednesday, April 23rd. Morgan Stanley cut their price objective on shares of PetMed Express from $3.50 to $3.20 and set an "underweight" rating on the stock in a research report on Thursday, April 17th.

Insider Activity at PetMed Express

In other PetMed Express news, CEO Sandra Yvette Campos sold 60,463 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $3.31, for a total value of $200,132.53. Following the completion of the sale, the chief executive officer now directly owns 578,524 shares of the company's stock, valued at $1,914,914.44. The trade was a 9.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.10% of the stock is owned by corporate insiders.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.